Skip to main content
DrugPrice

Meloxicam

Meloxicam

$6.00
avg cost per claim
-22.4% year-over-year
Reviewed by DrugPrice Editorial Team · Updated
$89.0M
Medicare Spending
14,580,000
Total Claims
2,140,000
Beneficiaries
$42.00
Annual Cost/Patient

Track Meloxicam price changes

Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.

Why Meloxicam Costs $6.00 Per Claim

Meloxicam (Meloxicam) is used to treat pain. According to CMS Medicare Part D spending data, the program spent $89.0M on this drug, covering 2,140,000 beneficiaries across 14,580,000 claims.

A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Meloxicam or talk to their doctor about therapeutic alternatives that may cost less.

Spending on Meloxicam decreased by 22.4% year-over-year, likely due to generic competition reducing prices.

Price Breakdown

Avg cost per claim (30-day)$6.00
Avg annual cost per patient$42.00
Total Medicare spending$89.0M
Total claims14,580,000
Beneficiaries2,140,000

Drug Details

Brand Name
Meloxicam
Generic Name
Meloxicam
Active Ingredient
Meloxicam
Manufacturer
Boehringer Ingelheim
Dosage Form
N/A
Route
N/A
Condition
Pain
FDA Application
BLA125057

Frequently Asked Questions

Meloxicam (Meloxicam) costs an average of $6.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $42.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.

Meloxicam averages $6.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.

A typical 30-day supply of Meloxicam reflects in our Medicare Part D average of $6.00 per claim. Switching to generic Meloxicam typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.

Most commercial insurance plans and Medicare Part D plans cover Meloxicam, but coverage varies by formulary tier. Insurers typically prefer generic Meloxicam (Tier 1, lowest copay) over brand-name Meloxicam (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.

Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Meloxicam is the single biggest cost reducer if your prescriber is open to it.

Brand-name Meloxicam costs more than generic Meloxicam primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.

Yes, a generic version of Meloxicam (Meloxicam) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Meloxicam.

Medicare Part D spent $89.0M on Meloxicam, covering 2,140,000 beneficiaries across 14,580,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.

Ask your pharmacist about generic Meloxicam, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.

Reading Meloxicam's Medicare Pricing

Meloxicam averages $6.00 per Part D claim, near the commodity end of the price spectrum — the range where generics and long-established molecules for pain sit. A low per-claim cost usually means robust generic competition or an old, cheaply-manufactured active ingredient (Meloxicam). At this price the bigger driver of total Medicare spending is volume, not unit price.

Medicare spent $89.0M on Meloxicam across 14,580,000 claims and 2,140,000 beneficiaries — a mid-size line item. Drugs in this tier rarely make headlines but collectively make up the bulk of Part D spending. The interplay between the $6.00 average claim cost and the claim volume is what decides whether this drug's total trends up or down year to year.

Because a generic version of Meloxicam is on the market, the realistic savings path for Meloxicam is straightforward: the generic is therapeutically equivalent and typically costs a fraction of the brand. The friction is usually prescribing habit rather than availability — patients can ask the prescriber to write for the generic, and most plans already steer to it with a lower copay tier. That single switch usually beats coupons, assistance programs, and pharmacy shopping combined.

Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $6.00 as a consistent Medicare-program benchmark for Meloxicam, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.